Furthermore, COTI-2 prominently suppresses tumor growth in HT-29 human colorectal tumor xenografts at a dosage of 10 mg/kg, effectively reducing tumor sizes at specific intervals post-treatment and extending the period for tumors to reach certain sizes. Remarkably, COTI-2 also significantly curtails tumor growth in the SHP-77 small cell lung cancer (SCLC) xenograft model with doses as minimal as 3 mg/kg. In treatments involving U87-MG tumors, COTI-2 not only shrinks tumor volumes at designated times after treatment but also prolongs the duration needed for the growth of U87-MG xenografts in nude mice^[2].

After 72 hours of treatment with COTI-2, there's a notable inhibition in the proliferation rates across all examined cell lines, including COLO-205, HCT-15, and SW620, demonstrating significant antiproliferative effects. COTI-2 also displays activity against several human glioblastoma cell lines, including U87-MG, SNB-19, SF-268, and SF-295, at relatively low concentrations. In SHP-77 cells treated with COTI-2 at approximate IC50 concentrations, early apoptosis is induced in 40 to 47% of the total cells^[2].